Home > Neurology > MTIS 2020 > Contents > Early initiation of lasmiditan improves migraine outcomes

Early initiation of lasmiditan improves migraine outcomes

Presented By
Dr Mario F. Peres, Hospital Israelita Albert Einstein, Brazil
Conference
MTIS 2020
Trial
Phase 3, GLADIATOR
The open-label, 12-month, phase 3 GLADIATOR trial evaluated the efficacy of the novel, selective 5-HT1F receptor agonist lasmiditan in treating migraine attacks of mild versus moderate or severe pain severity [1]. Treating migraine attacks at mild pain showed a tendency to relatively better efficacy outcomes, suggesting that earlier dosing is beneficial. It is recommended to treat acute migraine attacks early, when pain is mild. In two phase 3, placebo-controlled, single-attack clinical trials (SAMURAI and SPARTAN), lasmiditan was superior to placebo in treating moderate-to-severe migraine attacks. However, few mild attacks were stu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on